Dr. Hannu Alho received his MD in 1981 from the University of Tampere, Finland. After his MD/PhD Thesis in 1984 from University of Tampere, he was a Visiting Fellow at the NIMH in Washington DC, USA in 1984-86 and Associate Professor at Georgetown University in 1986-89. He received the specialty of Addiction Medicine in 2001. Since 2006 he has been a research Professor at National Institute of Health and Welfare, Helsinki Finland, and since 2008 Full Professor of Addiction Medicine at the University of Helsinki, Finland. He is also the Chief Physician at the Unit of Substance Use Abuse at the Helsinki University Hospital. Professor Alho has been a Board Member of the International Society of Addiction Medicine (ISAM) since 2001, and he has been the ISAM President 2011-14.
His main scientific interests are related to the neurobiology of addictions, the pharmacological treatment of substance use disorders and behavioral addictions. He has been Primary Investigator of several randomized controlled clinical trials, which are mainly focused on opioid antagonists, naltrexone, nalmefene and naloxone. Professor Alho’s research team was one of the first to demonstrate that targeted (as needed) opiate antagonist treatment naltrexone is effective in reducing alcohol consumption, and since then he has been active in the development and testing of related treatments such as gambling dependence.
In 2016 he received the Addiction Specialist Award from the Finnish Society of Addiction Medicine. He is an author of more than 240 peer reviewed scientific papers (H-index =41) and has been Supervisor for 18 MD/PhD Thesis. He is currently one of the editors of Substance Abuse Journal and is the Chief Editor of the Finnish Current Care Treatment Guidelines on Alcohol and Substance Use Disorders.